In multiple myeloma (MM)  there is a growing body of evidence showing the importance of minimal residual disease (MRD) monitoring  particularly among transplant-ineligible patients Paiva and colleagues assessed the clinical relevance of MRD monitoring in 163 elderly MM patients enrolled in the PETHEMA/GEM2010MAS65 trial of sequential bortezomib/melphalan/prednisone (VMP) followed by a lenalidomide/low-dose dexamethasone (Rd) regimen for 9 cycles each  or alternating cycles of VMP and Rd up to 18 cycles